MENLO PARK, Calif., Oct. 28, 2013 /PRNewswire/ -- Neodyne Biosciences, Inc., today announced 94 percent market adoption and a 91 percent re-order rate of embrace® Advanced Scar Therapy among active plastic surgeons in Las Vegas, Nevada. High physician and patient ratings of the company's first commercially available product have led to the rapid adoption of embrace® in the Las Vegas test market.
Patented embrace® Advanced Scar Therapy delivers a unique mechanism of action to off-load tension across a newly formed scar, and has been proven to significantly improve scar appearance in randomized, controlled studies. The product was recently featured during the "Hot Topics in Plastic Surgery" scientific session at the 2013 Annual Meeting of the American Society of Plastic Surgery on October 11th in San Diego, California.
"My patients often ask how they can minimize their scars after surgery," said plastic surgeon, Dr. Arthur Cambeiro of Las Vegas, Nevada, "and embrace® is the only product on the market that actually reduces the mechanical forces and tension on the newly formed scar, leading to better outcomes and overall satisfaction for my patients."
The Active Stress-Shielding Technology in embrace® and its proven clinical benefits have appealed to 94 percent of plastic surgeons in Las Vegas who are either currently using the product or have purchased it for scheduled patient procedures. The reception by these surgeons as well as their patients has been overwhelmingly positive.
"We are pleased with our growth and market penetration in Las Vegas and believe that embrace® Advanced Scar Therapy will become the standard of care for all patients concerned with the risk of post-surgical scarring," said Bill Beasley, President and COO of Neodyne. "Our success in Las Vegas gives us great momentum as we begin to expand our sales force presence."
About Neodyne Biosciences, Inc.
Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.
 Lim AF, et al. The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Control Trial. (In press, Plastic and Reconstructive Surgery)
SOURCE Neodyne Biosciences, Inc.